Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CD45RA-depleted DLI

Phase 2Biologic

SSt. Jude Children's Research Hospital

CD45RA-depleted DLI is one of 70 biologic programs targeting Memory. It is currently in Phase 2.

3

Indications

4

Total Trials

3

Active Trials

69

Competitors

Pipeline

Status by Indication[3][1]

Indication

MemoryActive, not recruiting

Severe Aplastic AnemiaActive, not recruiting

Hematologic MalignancyNot yet recruiting

MemoryPhase 2

Active, not recruiting

Severe Aplastic AnemiaPhase 2

Active, not recruiting

Hematologic MalignancyPhase 1

Not yet recruiting

Competition

Competitive Landscape

169 competitors in Memory

#DrugCompanyPhaseTrials

Lexapro

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Vivarin

HHikma Pharmaceuticals LLC

Pneumococcal Vaccine

Bupropion XL

Epidiolex

Jazz Pharmaceuticals

Rituxan

Cytoxan

BBaxter Healthcare Corporation

Rapamune

PPrism Pharmaceuticals

Solanezumab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Hematologic Malignancy

NCT07672964

Q3 2030

Phase 2Recruiting

Severe Aplastic Anemia

NCT04558736

Clinical

Trials by Indication[1]

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

Memory1 trial

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03849651·69 enrolled

Severe Aplastic Anemia1 trial

Haploidentical HCT for Severe Aplastic Anemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04558736·21 enrolled

Hematologic Malignancy1 trial

CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07672964·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CD45RA-depleted DLI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD45RA-depleted DLI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD45RA-depleted DLI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

Related News